Scopus: 1 cites, Web of Science: 1 cites,
Metabolomics of Therapy Response in Preclinical Glioblastoma : a Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment
Arias-Ramos, Nuria (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular)
Ferrer-Font, Laura (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular)
Lope Piedrafita, Silvia (Universitat Autònoma de Barcelona. Servei de Ressonància Magnètica Nuclear)
Mocioiu, Victor (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Julià Sapé, Ma. Margarita (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Pumarola i Batlle, Martí (Universitat Autònoma de Barcelona. Departament de Medicina i Cirurgia Animals)
Arús i Caraltó, Carles (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular)
Candiota Silveira, Ana Paula (Universitat Autònoma de Barcelona. Departament de Bioquímica i Biologia Molecular)

Data: 2017
Resum: Glioblastoma (GBM) is the most common aggressive primary brain tumor in adults, with a short survival time even after aggressive therapy. Non-invasive surrogate biomarkers of therapy response may be relevant for improving patient survival. Previous work produced such biomarkers in preclinical GBM using semi-supervised source extraction and single-slice Magnetic Resonance Spectroscopic Imaging (MRSI). Nevertheless, GBMs are heterogeneous and single-slice studies could prevent obtaining relevant information. The purpose of this work was to evaluate whether a multi-slice MRSI approach, acquiring consecutive grids across the tumor, is feasible for preclinical models and may produce additional insight into therapy response. Nosological images were analyzed pixel-by-pixel and a relative responding volume, the Tumor Responding Index (TRI), was defined to quantify response. Heterogeneous response levels were observed and treated animals were ascribed to three arbitrary predefined groups: high response (HR, n = 2), TRI = 68. 2 ± 2. 8%, intermediate response (IR, n = 6), TRI = 41. 1 ± 4. 2% and low response (LR, n = 2), TRI = 13. 4 ± 14. 3%, producing therapy response categorization which had not been fully registered in single-slice studies. Results agreed with the multi-slice approach being feasible and producing an inverse correlation between TRI and Ki67 immunostaining. Additionally, ca. 7-day oscillations of TRI were observed, suggesting that host immune system activation in response to treatment could contribute to the responding patterns detected.
Nota: Número d'acord de subvenció EC/FP7/316679
Nota: Número d'acord de subvenció MINECO/SAF2014-52332-R
Nota: Número d'acord de subvenció MINECO/BES-2012-055741
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès.
Document: article ; recerca ; publishedVersion
Matèria: Glioma ; GL261 ; Orthotopic tumors ; Therapy response ; TMZ ; Immune response ; Nosological images
Publicat a: Metabolites, Vol. 7, Num. 2 (2017) , p. p1-29, ISSN 2218-1989

DOI: 10.3390/metabo7020020
PMID: 28524099


29 p, 14.8 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats

 Registre creat el 2017-10-17, darrera modificació el 2018-06-16



   Favorit i Compartir